The DOI matches its Crossref record; 84 of the 84 references it cites were found in a registry or an index.
Beyond THC: The New Generation of Cannabinoid Designer Drugs
Open accessAbstract
Synthetic cannabinoids are functionally similar to delta9-tetrahydrocannabinol (THC), the psychoactive principle of cannabis, and bind to the same cannabinoid receptors in the brain and peripheral organs. From 2008, synthetic cannabinoids were detected in herbal smoking mixtures sold on websites and in "head shops" under the brand name of Spice Gold, Yucatan Fire, Aroma, and others. Although these products (also known as "Spice drugs" or "legal highs") do not contain tobacco or cannabis, when smoked they produce effects similar to THC. Intoxication, withdrawal, psychosis, and death have been recently reported after consumption, posing difficult social, political, and health challenges. More than 140 different Spice products have been identified to date. The ability to induce strong cannabis-like psychoactive effects, along with the fact that they are readily available on the Internet, still legal in many countries, marketed as natural safe substances, and undetectable by conventional drug screening tests, has rendered these drugs very popular and particularly appealing to young and drug-naïve individuals seeking new experiences. An escalating number of compounds with cannabinoid receptor activity are currently being found as ingredients of Spice, of which almost nothing is known in terms of pharmacology, toxicology, and safety. Since legislation started to control the synthetic cannabinoids identified in these herbal mixtures, many new analogs have appeared on the market. New cannabimimetic compounds are likely to be synthesized in the near future to replace banned synthetic cannabinoids, leading to a "dog chasing its tail" situation. Spice smokers are exposed to drugs that are extremely variable in composition and potency, and are at risk of serious, if not lethal, outcomes. Social and health professionals should maintain a high degree of alertness for Spice use and its possible psychiatric effects in vulnerable people.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
International Union of Pharmacology. XXVII. Classification of Cannabinoid Receptors
Howlett, A. C., Barth, F., Bonner, T. I., Cabral, G., Casellas, P., Devane, W. A., Felder, C. C., Herkenham, M., Mackie, K., Martin, B. R., et al. (2002) · Pharmacological Reviews · doi:10.1124/pr.54.2.161 · Cited by 2,819
Pertwee, R. G. (2008) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707442 · Cited by 1,935
Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study.
Arseneault, L., Cannon, M., Poulton, R., Murray, R., Caspi, A., & Moffitt, T. E. (2002) · BMJ · doi:10.1136/bmj.325.7374.1212 · Cited by 1,399
Bergamaschi, M. M., Queiroz, R. H. C., Chagas, M. H. N., de Oliveira, D. C. G., De Martinis, B. S., Kapczinski, F., Quevedo, J., Roesler, R., Schröder, N., Nardi, A. E., et al. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2011.6 · Cited by 771 · cited 2×
“Yet, these products provide very limited safety information about their effects and possible health consequences, so that uninformed users risk serious adverse effects.”
BackgroundThomas, A., Baillie, G. L., Phillips, A. M., Razdan, R. K., Ross, R. A., & Pertwee, R. G. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707133 · Cited by 756
‘Spice’ and other herbal blends: harmless incense or cannabinoid designer drugs?
Auwärter, V., Dresen, S., Weinmann, W., Müller, M., Pütz, M., & Ferreirós, N. (2009) · Journal of Mass Spectrometry · doi:10.1002/jms.1558 · Cited by 660
Dhawan, K., Dhawan, S., & Sharma, A. (2004) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2004.02.023 · Cited by 626
Action of cannabidiol on the anxiety and other effects produced by ?9-THC in normal subjects
Zuardi, A. W., Shirakawa, I., Finkelfarb, E., & Karniol, I. G. (1982) · Psychopharmacology · doi:10.1007/bf00432554 · Cited by 608
Crippa, J. A. S., Derenusson, G. N., Ferrari, T. B., Wichert-Ana, L., Duran, F. L., Martin-Santos, R., Simões, M. V., Bhattacharyya, S., Fusar-Poli, P., Atakan, Z., et al. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881110379283 · Cited by 535
Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug
Zuardi, A. W., Crippa, J. A. S., Hallak, J. E. C., Moreira, F. A., & Guimarães, F. S. (2006) · Brazilian Journal of Medical and Biological Research · doi:10.1590/s0100-879x2006000400001 · Cited by 402
Antianxiety effect of cannabidiol in the elevated plus-maze
Guimarães, F. S., Chiaretti, T. M., Graeff, F. G., & Zuardi, A. W. (1990) · Psychopharmacology · doi:10.1007/bf02244012 · Cited by 379 · cited 2×
“Interestingly, unlike cannabis, Spice blends do not contain cannabidiol, a phytocannabinoids known to possess anxiolytic properties, which is able to reduced anxiety in both animals (Guimarães et al., 1990; Moreira et al., 2006) and humans (Bergamaschi et al., 2011; Crippa et al., 2011).”
BackgroundThe cannabis withdrawal syndrome
Budney, A. J., & Hughes, J. R. (2006) · Current Opinion in Psychiatry · doi:10.1097/01.yco.0000218592.00689.e5 · Cited by 349
Spice drugs as a new trend: Mode of action, identification and legislation
Vardakou, I., Pistos, C., & Spiliopoulou, C. (2010) · Toxicology Letters · doi:10.1016/j.toxlet.2010.06.002 · Cited by 341
Dresen, S., Ferreirós, N., Pütz, M., Westphal, F., Zimmermann, R., & Auwärter, V. (2010) · Journal of Mass Spectrometry · doi:10.1002/jms.1811 · Cited by 309
Synthetic cannabinoid JWH-018 and psychosis: An explorative study
Every-Palmer, S. (2011) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2011.01.012 · Cited by 299
Lindigkeit, R., Boehme, A., Eiserloh, I., Luebbecke, M., Wiggermann, M., Ernst, L., & Beuerle, T. (2009) · Forensic Science International · doi:10.1016/j.forsciint.2009.06.008 · Cited by 299
Withdrawal Phenomena and Dependence Syndrome After the Consumption of „Spice Gold“
Zimmermann, U. S., Winkelmann, P. R., Pilhatsch, M., Nees, J. A., Spanagel, R., & Schulz, K. (2009) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2009.0464 · Cited by 278
Supply and demand for endocannabinoids
Alger, B. E., & Kim, J. (2011) · Trends in Neurosciences · doi:10.1016/j.tins.2011.03.003 · Cited by 268
Atwood, B. K., Huffman, J., Straiker, A., & Mackie, K. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00582.x · Cited by 262
Huffman, J. W., Zengin, G., Wu, M.-J., Lu, J., Hynd, G., Bushell, K., Thompson, A. L. S., Bushell, S., Tartal, C., Hurst, D. P., et al. (2005) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2004.09.050 · Cited by 259
Influence of the N-1 alkyl chain length of cannabimimetic indoles upon CB1 and CB2 receptor binding
Aung, M. M., Griffin, G., Huffman, J. W., Wu, M.-J., Keel, C., Yang, B., Showalter, V. M., Abood, M. E., & Martin, B. R. (2000) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(99)00152-0 · Cited by 254
Chemical analysis of synthetic cannabinoids as designer drugs in herbal products
Uchiyama, N., Kikura-Hanajiri, R., Ogata, J., & Goda, Y. (2010) · Forensic Science International · doi:10.1016/j.forsciint.2010.01.004 · Cited by 245
Structure-Activity Relationships of Indole- and Pyrrole-Derived Cannabinoids
Wiley, J. L., Compton, D. R., Dai, D., Lainton, J. A. H., Phillips, M., Huffman, J. W., & Martin, B. R. (1998) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37496-8 · Cited by 240
Detection of JWH-018 metabolites in smoking mixture post-administration urine
Sobolevsky, T. G., Prasolov, I., & Rodchenkov, G. M. (2010) · Forensic Science International · doi:10.1016/j.forsciint.2010.04.003 · Cited by 219
Teske, J., Weller, J.-P., Fieguth, A., et al. (2010) · Journal of Chromatography B · doi:10.1016/j.jchromb.2010.03.016 · Cited by 216
Compton, D. R., Johnson, M. R., Melvin, L. S., & Martin, B. R. (1992) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)11216-0 · Cited by 215
“Spice” Girls: Synthetic Cannabinoid Intoxication
Schneir, A. B., Cullen, J., & Ly, B. T. (2011) · The Journal of Emergency Medicine · doi:10.1016/j.jemermed.2010.10.014 · Cited by 215
Brents, L. K., Reichard, E. E., Zimmerman, S. M., Moran, J. H., Fantegrossi, W. E., & Prather, P. L. (2011) · PLoS ONE · doi:10.1371/journal.pone.0021917 · Cited by 214
Anxiolytic-like effect of cannabidiol in the rat Vogel conflict test
Moreira, F. A., Aguiar, D. C., & Guimarães, F. S. (2006) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2006.06.004 · Cited by 207
Kronstrand, R., Roman, M., Thelander, G., & Eriksson, A. (2011) · Journal of Analytical Toxicology · doi:10.1093/anatox/35.4.242 · Cited by 198
“Legal highs” on the net—Evaluation of UK-based Websites, products and product information
Schmidt, M. M., Sharma, A., Schifano, F., & Feinmann, C. (2011) · Forensic Science International · doi:10.1016/j.forsciint.2010.06.030 · Cited by 197
Müller, H., Sperling, W., Köhrmann, M., Huttner, H. B., Kornhuber, J., & Maler, J.-M. (2010) · Schizophrenia Research · doi:10.1016/j.schres.2009.12.001 · Cited by 183
Oleamide is a selective endogenous agonist of rat and human CB1 cannabinoid receptors
Leggett, J. D., Aspley, S., Beckett, S. R. G., D'Antona, A. M., Kendall, D. A., & Kendall, D. A. (2004) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0705607 · Cited by 174
Identification of a Cannabinoid Analog as a New Type of Designer Drug in a Herbal Product
Uchiyama, N., Kikura-Hanajiri, R., Kawahara, N., Haishima, Y., & Goda, Y. (2009) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.57.439 · Cited by 172
Hillebrand, J., Olszewski, D., & Sedefov, R. (2010) · Substance Use & Misuse · doi:10.3109/10826080903443628 · Cited by 172
Drugs for youth via Internet and the example of mephedrone
Vardakou, I., Pistos, C., & Spiliopoulou, C. (2011) · Toxicology Letters · doi:10.1016/j.toxlet.2010.12.014 · Cited by 170
Dresen, S., Kneisel, S., Weinmann, W., Zimmermann, R., & Auwärter, V. (2011) · Journal of Mass Spectrometry · doi:10.1002/jms.1877 · Cited by 155
Fortunato, J. J., Réus, G. Z., Kirsch, T. R., Stringari, R. B., Stertz, L., Kapczinski, F., Pinto, J. P., Hallak, J. E., Zuardi, A. W., Crippa, J. A., et al. (2009) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2009.07.021 · Cited by 150
Huffman, J. W., Mabon, R., Wu, M., Lu, J., Hart, R., Hurst, D. P., Reggio, P. H., Wiley, J. L., & Martin, B. R. (2003) · Bioorganic & Medicinal Chemistry · doi:10.1016/s0968-0896(02)00451-0 · Cited by 149
The emergence and analysis of synthetic cannabinoids
Hudson, S. C., & Ramsey, J. M. (2011) · Drug Testing and Analysis · doi:10.1002/dta.268 · Cited by 145
In vitro phase I metabolism of the synthetic cannabimimetic JWH-018
Wintermeyer, A., Möller, I., Thevis, M., Jübner, M., Beike, J., Rothschild, M. A., & Mercer‐Chalmers‐Bender, K. (2010) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-010-4171-0 · Cited by 144
Identification of a cannabimimetic indole as a designer drug in a herbal product
Uchiyama, N., Kikura‐Hanajiri, R., Kawahara, N., & Goda, Y. (2009) · Forensic Toxicology · doi:10.1007/s11419-009-0069-y · Cited by 141
College students and use of K2: an emerging drug of abuse in young persons
Hu, X., Primack, B. A., Barnett, T. E., et al. (2011) · Substance Abuse Treatment Prevention and Policy · doi:10.1186/1747-597x-6-16 · Cited by 140
Marijuana-based Drugs: Innovative Therapeutics or Designer Drugs of Abuse?
Seely, K. A., Prather, P. L., James, L. P., & Moran, J. H. (2011) · Molecular Interventions · doi:10.1124/mi.11.1.6 · Cited by 133
Grigoryev, A., Savchuk, S. A., Melnik, A., et al. (2011) · Journal of Chromatography B · doi:10.1016/j.jchromb.2011.03.034 · Cited by 132
Hudson, S. C., Ramsey, J., King, L. A., Timbers, S., Maynard, S., Dargan, P. I., & Wood, D. M. (2010) · Journal of Analytical Toxicology · doi:10.1093/jat/34.5.252 · Cited by 124
Uchiyama, N., Kawamura, M., Kikura‐Hanajiri, R., & Goda, Y. (2010) · Forensic Toxicology · doi:10.1007/s11419-010-0100-3 · Cited by 122
Three cases of “spice” exposure
Simmons, J. R., Cookman, L., Kang, C., et al. (2011) · Clinical Toxicology · doi:10.3109/15563650.2011.584316 · Cited by 118
Atwood, B. K., Lee, D., Straiker, A. J., Widlanski, T. S., & Mackie, K. (2011) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2011.01.066 · Cited by 114
Learning Impairment Produced in Rats by the Cannabinoid Agonist HU 210 in a Water-Maze Task
Ferrari, F., Ottani, A., Vivoli, R., & Giuliani, D. (1999) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(99)00106-9 · Cited by 113
Fortunato, J. J., Réus, G. Z., Kirsch, T. R., Stringari, R. B., Fries, G. R., Kapczinski, F. P., Hallak, J. E. C., Zuardi, A. W., Crippa, J. A. S., & Quevedo, J. (2009) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2009.09.008 · Cited by 108
Behavioral Evidence for the Interaction of Oleamide with Multiple Neurotransmitter Systems
Fedorova, I. M., Hashimoto, A., Fecik, R. A., Hedrick, M. P., Hanuš, L. O., Boger, D. L., Rice, K. C., & Basile, A. S. (2001) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)29334-4 · Cited by 107
Cannabimimetic activity from CP-47,497, a derivative of 3-phenylcyclohexanol.
Weissman, A., Milne, G. M., & Melvin, L. S. (1982) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)33364-1 · Cited by 107
Comparison of “herbal highs” composition
Zuba, D., Byrska, B., & Maciów, M. (2011) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-011-4743-7 · Cited by 101
Drugs on the web; the Psychonaut 2002 EU project
Schifano, F., Deluca, P., Baldacchino, A., Peltoniemi, T., Scherbaum, N., Torrens, M., Farré, M., Flores, I., Rossi, M., Eastwood, D., et al. (2006) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2005.11.035 · Cited by 101
Every‐Palmer, S. (2010) · Addiction · doi:10.1111/j.1360-0443.2010.03119.x · Cited by 99
Malone, D. T., Jongejan, D., & TAYLOR, D. A. H. B. (2009) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2009.04.010 · Cited by 99
Corazza, O., Schifano, F., Farré, M., Deluca, P., Davey, Z., Drummond, C., Torrens, M., Demetrovics, Z., Furia, L. D., Flesland, L., et al. (2011) · Current Clinical Pharmacology · doi:10.2174/157488411796151129 · Cited by 97
Intoxication From Smoking “Spice”
Simmons, J. R., Skinner, C. G., Williams, J., et al. (2011) · Annals of Emergency Medicine · doi:10.1016/j.annemergmed.2010.08.039 · Cited by 95
Basic pharmacology relevant to drug abuse assessment: tramadol as example
Raffa, R. B. (2008) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/j.1365-2710.2008.00897.x · Cited by 89
Vearrier, D., & Osterhoudt, K. C. (2010) · Pediatric Emergency Care · doi:10.1097/pec.0b013e3181e4f416 · Cited by 87
Latest advances in cannabinoid receptor agonists
Thakur, G. A., Tichkule, R. B., Bajaj, S., & Makriyannis, A. (2009) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543770903436505 · Cited by 87
Ernst, L., Schiebel, H., Theuring, C., Lindigkeit, R., & Beuerle, T. (2011) · Forensic Science International · doi:10.1016/j.forsciint.2011.03.020 · Cited by 86
Schifano, F., Leoni, M., Martinotti, G., Rawaf, S., & Rovetto, F. M. (2003) · CyberPsychology & Behavior · doi:10.1089/109493103322278790 · Cited by 78
Schifano, F., Corazza, O., Deluca, P., Davey, Z., Furia, L. D., Farré, M., Flesland, L., Mannonen, M., Pagani, S., Peltoniemi, T., et al. (2009) · International Journal of Culture and Mental Health · doi:10.1080/17542860903350888 · Cited by 77
Chin, C., Murphy, J. W., Huffman, J. W., et al. (1999) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)35174-2 · Cited by 75
Beuck, S., Möller, I., Thomas, A., et al. (2011) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-011-4931-5 · Cited by 74
Survey of current trends in the abuse of psychotropic substances and plants in Japan
Kikura‐Hanajiri, R., Uchiyama, N., & Goda, Y. (2011) · Legal Medicine · doi:10.1016/j.legalmed.2011.02.003 · Cited by 72
Huffman, J. W. (2008) · Humana Press eBooks · doi:10.1007/978-1-59745-503-9_3 · Cited by 71
Zhang, Q., Ma, P., Cole, R. B., & Wang, G. (2006) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-006-0717-6 · Cited by 71
Maćkowiak, M., Chocyk, A., Dudys, D., & Wędzony, K. (2008) · Neuroscience · doi:10.1016/j.neuroscience.2008.11.037 · Cited by 65
Psychiatric Sequelae of Spice, K2, and Synthetic Cannabinoid Receptor Agonists
Benford, D. M., & Caplan, J. P. (2011) · Psychosomatics · doi:10.1016/j.psym.2011.01.004 · Cited by 65
Spice: A New “Legal” Herbal Mixture Abused by Young Active Duty Military Personnel
Bebarta, V. S., Ramirez, S., & Varney, S. M. (2012) · Substance Abuse · doi:10.1080/08897077.2011.637610 · Cited by 63
Robinson, L., Goonawardena, A. V., Pertwee, R. G., Hampson, R. E., & Riedel, G. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707273 · Cited by 62
Web Sites with Misinformation about Illicit Drugs
Boyer, E. W., Shannon, M. W., & Hibberd, P. L. (2001) · New England Journal of Medicine · doi:10.1056/nejm200108093450619 · Cited by 61
“Legal Highs” – New Players in the Old Drama
Zawilska, J. B. (2011) · Current Drug Abuse Reviews · doi:10.2174/1874473711104020122 · Cited by 61
Investigating a not-so-natural high
Piggee, C. A. (2009) · Analytical Chemistry · doi:10.1021/ac900564u · Cited by 59
Inhibitory effects of the cannabinoid agonist HU 210 on rat sexual behaviour
Ferrari, F., Ottani, A., & Giuliani, D. (2000) · Physiology & Behavior · doi:10.1016/s0031-9384(00)00214-6 · Cited by 57
Nakajima, J., Takahashi, M., Seto, T., & Suzuki, J. (2010) · Forensic Toxicology · doi:10.1007/s11419-010-0101-2 · Cited by 56
DANGERS OF BANNING SPICE AND THE SYNTHETIC CANNABINOID AGONISTS
Hammersley, R. (2010) · Addiction · doi:10.1111/j.1360-0443.2009.02845.x · Cited by 44
Identification of 1-butyl-3-(1-(4-methyl)naphthoyl)indole in a herbal mixture
Westphal, F., Sönnichsen, F. D., & Thiemt, S. (2011) · Forensic Science International · doi:10.1016/j.forsciint.2011.03.031 · Cited by 44
Synthesis and pharmacology of 1-deoxy analogs of CP-47,497 and CP-55,940
Huffman, J. W., Thompson, A. L. S., Wiley, J. L., & Martin, B. R. (2007) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2007.09.033 · Cited by 36
Effects of synthetic cannabinoids on electroencephalogram power spectra in rats
Uchiyama, N., Kikura‐Hanajiri, R., Matsumoto, N., Huang, Z., Goda, Y., & Urade, Y. (2011) · Forensic Science International · doi:10.1016/j.forsciint.2011.05.005 · Cited by 16
ZULLINO, D. F., Rathelot, T., & Khazaal, Y. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61653-5 · Cited by 14
Cited by
Seely, K. A., Lapoint, J., Moran, J. H., & Fattore, L. (2012) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2012.04.017 · Cited by 465
Self-citationHassan, Z., Muzaimi, M., Navaratnam, V., Yusoff, N. H. M., Suhaimi, F. W., Vadivelu, R., Vicknasingam, B. K., Amato, D., von Hörsten, S., Ismail, N. I. W., et al. (2013) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2012.11.012 · Cited by 386
Stout, S. M., & Cimino, N. M. (2014) · Drug Metabolism Reviews · doi:10.3109/03602532.2013.849268 · Cited by 347
Winstock, A. R., & Barratt, M. J. (2013) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2012.12.011 · Cited by 331
Novel psychoactive substances of interest for psychiatry
Schifano, F., Orsolini, L., Duccio Papanti, G., & Corkery, J. M. (2015) · World Psychiatry · doi:10.1002/wps.20174 · Cited by 321
Metadata
- Authors
- Fattore, L., & Fratta, W.
- Venue
- Frontiers in Behavioral Neuroscience
- Publisher
- Frontiers Media SA
- Published
- 2011
- Volume
- 5
- Pages
- 60-60
- ISSN
- 1662-5153 (ISSN-L)
- OpenAlex
- W2016055866
- Cited by
- 443
- References
- 84
- FWCI
- 44.81
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.